JP Morgan: BioLineRx Will Outperform, Is Worth $5/Share On 'Promising Technology'
June 22, 2015 at 09:54 AM EDT
In a report published Monday, JPMorgan analysts initiated coverage of Bioline RX Ltd (NASDAQ: BLRX) with an Outperform rating and $5 ...